• Je něco špatně v tomto záznamu ?

Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trial

V. Bril, T. Berkowicz, A. Szczudlik, MW. Nicolle, J. Bednarik, P. Hon, A. Vaitkus, T. Vu, C. Rozsa, T. Magnus, G. Panczel, T. Toomsoo, M. Pasnoor, T. Mozaffar, M. Freimer, U. Reuner, L. Vécsei, N. Souayah, T. Levine, RM. Pascuzzi, MC. Dalakas, M....

. 2025 ; 71 (1) : 43-54. [pub] 20241107

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, klinické zkoušky, fáze II

Perzistentní odkaz   https://www.medvik.cz/link/bmc25002880

Grantová podpora
Grifols Therapeutics LLC

INTRODUCTION/AIMS: Prospective, randomized, controlled trials of intravenous immunoglobulin (IVIG) maintenance therapy in myasthenia gravis (MG) are lacking. In this trial, we evaluated the safety and efficacy of caprylate/chromatography-purified IVIG; (IGIV-C) in patients with generalized MG undergoing standard care. METHODS: Sixty-two patients enrolled in this phase 2, multicenter, international, randomized trial (1:1 IGIV-C [2 g/kg loading dose; 1 g/kg every 3 weeks through week 21] or placebo). Efficacy was assessed by changes in Quantitative MG (QMG) score at week 24 versus baseline (primary endpoint) and percentage of patients with clinical improvement in QMG, MG Composite (MGC), and MG-Activities of Daily Living (MG-ADL) scores (secondary endpoints). Safety assessments reported all adverse events (AEs). RESULTS: The change in QMG at 24 weeks was -5.1 for IGIV-C and -3.1 for placebo (p = .187). Seventy percent of patients in the IGIV-C group had improvement in MG-ADL (≥2-point decrease) versus 40.6% in the placebo group (p = .025). Patients showing clinical improvement in QMG and MGC (≥3-point decrease) were 70.0% for IGIV-C versus 59.4% for placebo (p = .442) and 60.0% for IGIV-C versus 53.1% for placebo (p = .610). IGIV-C was well tolerated; serious AEs were similar between arms. Three of four MG exacerbations requiring hospitalizations occurred in the IGIV-C arm with one death. DISCUSSION: Several efficacy parameters showed numerical results greater than those seen in the placebo group. This was a small study and may have been underpowered to see significant differences. Additional studies may be warranted to fully determine the efficacy of IVIG maintenance therapy in MG.

3 Miejskie Centrum Medyczne im Dr Karola Jonschera w Łodzi Lodz Poland

Centrum Neurologii Klinicznej Krakow Poland

Department of Neurology Albert Szent Györgyi Clinical Center University of Szeged Szeged Hungary

Department of Neurology Flór Ferenc County Hospital Kistarcsa Hungary

Department of Neurology Hospital of Lithuanian University of Health Sciences Kaunas Clinics Kaunas Lithuania

Department of Neurology Rutgers New Jersey Medical School Newark New Jersey USA

Department of Neurology The Ohio State University Columbus Ohio USA

Department of Neurology Thomas Jefferson University Philadelphia Pennsylvania USA

Department of Neurology University Clinic Dresden Technische Universität Dresden Dresden Germany

Department of Neurology University Hospital Brno and Faculty of Medicine Masaryk University Brno Czech Republic

Department of Neurology University of Kansas Medical Center Kansas City Kansas USA

Department of Neurology University of South Florida Morsani College of Medicine Tampa Florida USA

East Tallinn Central Hospital Tallinn Estonia

Fakultni Nemocnice Ostrava Neurologicka Klinika Ostrava Poruba Czech Republic

Grifols Bioscience Research Group Research Triangle Park North Carolina USA

Grifols Bioscience Research Group Sant Cugat Spain

Honor Health Neurology Scottsdale Arizona USA

Indiana School of Medicine Indianapolis Indiana USA

Jahn Ferenc Del pesti Korhaz es Rendelointezet Neurologiai Osztaly Budapest Hungary

London Health Sciences Centre and Western University London Ontario Canada

National and Kapodistrian University of Athens Athens Greece

Neurology EMG Laboratory Augusta University Augusta Georgia USA

Toronto General Hospital Toronto Ontario Canada

Universitaetsklinikum Hamburg Eppendorf Klinik und Poliklinik fuer Neurologie Neurologische Studienzentrale Hamburg Germany

University of California Irvine Orange California USA

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25002880
003      
CZ-PrNML
005      
20250206103924.0
007      
ta
008      
250121s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/mus.28289 $2 doi
035    __
$a (PubMed)39506903
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bril, Vera $u Toronto General Hospital, Toronto, Ontario, Canada $1 https://orcid.org/0000000258054883
245    10
$a Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trial / $c V. Bril, T. Berkowicz, A. Szczudlik, MW. Nicolle, J. Bednarik, P. Hon, A. Vaitkus, T. Vu, C. Rozsa, T. Magnus, G. Panczel, T. Toomsoo, M. Pasnoor, T. Mozaffar, M. Freimer, U. Reuner, L. Vécsei, N. Souayah, T. Levine, RM. Pascuzzi, MC. Dalakas, M. Rivner, R. Griffin, MQ. Coll, E. Mondou
520    9_
$a INTRODUCTION/AIMS: Prospective, randomized, controlled trials of intravenous immunoglobulin (IVIG) maintenance therapy in myasthenia gravis (MG) are lacking. In this trial, we evaluated the safety and efficacy of caprylate/chromatography-purified IVIG; (IGIV-C) in patients with generalized MG undergoing standard care. METHODS: Sixty-two patients enrolled in this phase 2, multicenter, international, randomized trial (1:1 IGIV-C [2 g/kg loading dose; 1 g/kg every 3 weeks through week 21] or placebo). Efficacy was assessed by changes in Quantitative MG (QMG) score at week 24 versus baseline (primary endpoint) and percentage of patients with clinical improvement in QMG, MG Composite (MGC), and MG-Activities of Daily Living (MG-ADL) scores (secondary endpoints). Safety assessments reported all adverse events (AEs). RESULTS: The change in QMG at 24 weeks was -5.1 for IGIV-C and -3.1 for placebo (p = .187). Seventy percent of patients in the IGIV-C group had improvement in MG-ADL (≥2-point decrease) versus 40.6% in the placebo group (p = .025). Patients showing clinical improvement in QMG and MGC (≥3-point decrease) were 70.0% for IGIV-C versus 59.4% for placebo (p = .442) and 60.0% for IGIV-C versus 53.1% for placebo (p = .610). IGIV-C was well tolerated; serious AEs were similar between arms. Three of four MG exacerbations requiring hospitalizations occurred in the IGIV-C arm with one death. DISCUSSION: Several efficacy parameters showed numerical results greater than those seen in the placebo group. This was a small study and may have been underpowered to see significant differences. Additional studies may be warranted to fully determine the efficacy of IVIG maintenance therapy in MG.
650    _2
$a lidé $7 D006801
650    12
$a myasthenia gravis $x farmakoterapie $7 D009157
650    12
$a intravenózní imunoglobuliny $x terapeutické užití $x škodlivé účinky $x aplikace a dávkování $7 D016756
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dospělí $7 D000328
650    12
$a receptory cholinergní $x imunologie $7 D011950
650    _2
$a senioři $7 D000368
650    _2
$a výsledek terapie $7 D016896
650    _2
$a autoprotilátky $x krev $7 D001323
650    _2
$a imunologické faktory $x terapeutické užití $x škodlivé účinky $x aplikace a dávkování $7 D007155
650    _2
$a činnosti denního života $7 D000203
650    _2
$a prospektivní studie $7 D011446
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a klinické zkoušky, fáze II $7 D017427
700    1_
$a Berkowicz, Tomasz $u III Miejskie Centrum Medyczne im, Dr Karola Jonschera w Łodzi, Lodz, Poland
700    1_
$a Szczudlik, Andrzej $u Centrum Neurologii Klinicznej, Krakow, Poland
700    1_
$a Nicolle, Michael W $u London Health Sciences Centre and Western University, London, Ontario, Canada
700    1_
$a Bednarik, Josef $u Department of Neurology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Hon, Petr $u Fakultni Nemocnice Ostrava, Neurologicka Klinika, Ostrava-Poruba, Czech Republic
700    1_
$a Vaitkus, Antanas $u Department of Neurology, Hospital of Lithuanian University of Health Sciences, Kaunas Clinics, Kaunas, Lithuania
700    1_
$a Vu, Tuan $u Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, Florida, USA $1 https://orcid.org/0000000307240210
700    1_
$a Rozsa, Csilla $u Jahn Ferenc Del-pesti Korhaz es Rendelointezet Neurologiai Osztaly, Budapest, Hungary
700    1_
$a Magnus, Tim $u Universitaetsklinikum Hamburg Eppendorf, Klinik und Poliklinik fuer Neurologie, Neurologische Studienzentrale, Hamburg, Germany
700    1_
$a Panczel, Gyula $u Department of Neurology, Flór Ferenc County Hospital, Kistarcsa, Hungary
700    1_
$a Toomsoo, Toomas $u East Tallinn Central Hospital, Tallinn, Estonia
700    1_
$a Pasnoor, Mamatha $u Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA
700    1_
$a Mozaffar, Tahseen $u University of California, Irvine, Orange, California, USA $1 https://orcid.org/0000000212300188
700    1_
$a Freimer, Miriam $u Department of Neurology, The Ohio State University, Columbus, Ohio, USA
700    1_
$a Reuner, Ulrike $u Department of Neurology, University Clinic Dresden, Technische Universität Dresden, Dresden, Germany
700    1_
$a Vécsei, László $u Department of Neurology, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary
700    1_
$a Souayah, Nizar $u Department of Neurology, Rutgers-New Jersey Medical School, Newark, New Jersey, USA
700    1_
$a Levine, Todd $u Honor Health Neurology, Scottsdale, Arizona, USA
700    1_
$a Pascuzzi, Robert M $u Indiana School of Medicine, Indianapolis, Indiana, USA
700    1_
$a Dalakas, Marinos C $u Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA $u National and Kapodistrian University of Athens, Athens, Greece
700    1_
$a Rivner, Michael $u Neurology/EMG Laboratory, Augusta University, Augusta, Georgia, USA
700    1_
$a Griffin, Rhonda $u Grifols Bioscience Research Group, Research Triangle Park, North Carolina, USA
700    1_
$a Coll, Montse Querolt $u Grifols Bioscience Research Group, Sant Cugat, Spain
700    1_
$a Mondou, Elsa $u Grifols Bioscience Research Group, Research Triangle Park, North Carolina, USA
773    0_
$w MED00003426 $t Muscle and nerve $x 1097-4598 $g Roč. 71, č. 1 (2025), s. 43-54
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39506903 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206103920 $b ABA008
999    __
$a ok $b bmc $g 2262962 $s 1238887
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 71 $c 1 $d 43-54 $e 20241107 $i 1097-4598 $m Muscle and nerve $n Muscle Nerve $x MED00003426
GRA    __
$p Grifols Therapeutics LLC
LZP    __
$a Pubmed-20250121

Najít záznam

Citační ukazatele

Možnosti archivace